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ABSTRACT
The transcription factor LSF is highly expressed in hepatocellular carcinoma 
(HCC) and promotes oncogenesis. Factor quinolinone inhibitor 1 (FQI1), inhibits LSF 
DNA-binding activity and exerts anti-proliferative activity. Here, we show that LSF 
binds directly to the maintenance DNA (cytosine-5) methyltransferase 1 (DNMT1) 
and its accessory protein UHRF1 both in vivo and in vitro. Binding of LSF to DNMT1 
stimulated DNMT1 activity and FQI1 negated the methyltransferase activation. 
Addition of FQI1 to the cell culture disrupted LSF bound DNMT1 and UHRF1 complexes, 
resulting in global aberrant CpG methylation. Differentially methylated regions (DMR) 
containing at least 3 CpGs, were significantly altered by FQI1 compared to control 
cells. The DMRs were mostly concentrated in CpG islands, proximal to transcription 
start sites, and in introns and known genes. These DMRs represented both hypo 
and hypermethylation, correlating with altered gene expression. FQI1 treatment 
elicits a cascade of effects promoting altered cell cycle progression. These findings 
demonstrate a novel mechanism of FQI1 mediated alteration of the epigenome by 
DNMT1-LSF complex disruption, leading to aberrant DNA methylation and gene 
expression.
INTRODUCTION
DNA methylation is one of the major mechanisms 
for the regulation of genetic information and gene 
expression in vertebrates [1]. It maintains gene silencing in 
the nuclear genome including the repetitive DNA elements 
[2, 3]. In this mechanism, a methyl group is covalently 
added at the 5th position of carbon on the cytosine ring 
in CG, CHG and CHH sequence contexts [4–7]. Loss of 
global DNA methylation on the repetitive DNA elements 
and subsequent alteration in chromatin structure was the 
first epigenetic change demonstrated in human cancers [8, 
9]. Subsequent studies have shown that numerous tumor-
suppressor genes in cancers are hypermethylated and 
transcriptionally silent [10]. Therefore, the observation 
of aberrant DNA methylation is considered a hallmark 
of human cancer. The most studied change of DNA 
methylation in neoplasms is the silencing of tumor 
suppressor genes by hypermethylation of associated CpG 
island promoters, for example p16 (INK4a), BRCA1, 
and hMLH1 [10–12]. Indeed, aberrant DNA methylation 
was demonstrated to be the dominant mechanism in 
MDS progression to AML correlating with poor clinical 
outcomes [13], highlighting its relevance to oncogenesis.
DNA methylation is carried out by three different 
DNA (cytosine-5) methyltransferases in humans, 
DNMT1, DNMT3A and DNMT3B [14, 15]. Amongst 
these three, DNMT3A and 3B are known as de novo 
methyltransferases, and their roles in early developmental 
DNA methylation pattern establishment is well studied 
in mouse model systems [14, 15]. DNMT1 is popularly 
known as the maintenance DNA methyltransferase as 
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it copies the original DNA methylation pattern onto the 
daughter strand during DNA replication [16]. DNMT1 
acts on hemimethylated DNA at the replication fork with 
a host of accessory proteins including UHRF1, which 
confers specificity to the enzyme [17–19]. Indeed, UHRF1 
is indispensable for maintenance DNA methylation and 
its null mutation results in hypomethylation of the ES 
genome [20]. The complex of DNMT1-UHRF1 and the 
clamp-loading factor PCNA are essential components of 
DNA methylation preservation during DNA replication. 
These observations suggest that there may be other protein 
factors including transcription factors that can influence 
DNA methylation by direct DNMT1 interaction. DNMT1 
is essential for embryonic development and its loss results 
in embryonic lethality [21]. Indeed, many cancer cells 
show deregulation of either or both DNMT1 and UHRF1, 
suggesting that aberrant DNA methylation is a result 
of deregulation of enzymes and essential protein factors 
[22, 23].
Several studies have demonstrated that methylation 
fidelity in normal cells is tightly regulated by one or 
more enzyme targeting mechanisms. These mechanisms 
include recruitment of enzymes via specific interactions 
with histone tail modifications or through protein partners 
including chromatin remodelers and transcription factors 
[24–27]. Similarly, lymphoid specific helicase (LSH) 
protein, which belongs to the family of switch sucrose 
non-fermentable (SWI/SNF) chromatin remodelers, has 
been found to play an essential role in de novo DNA 
methylation in mice, strengthening the connection 
between chromatin remodeling and DNA methylation 
[28]. Transcription factors such as p53 can directly 
interact and cooperate with DNMT1 to selectively repress 
p53-repressed genes such as survivin [25]. DNMT1 also 
binds Retinoblastoma protein (Rb) in a complex with 
the transcription factor E2F1 and HDAC1 to repress 
transcription from promoters containing E2F-binding 
sites [26]. Therefore sequence specific transcription 
factors often participate in DNA methylation programing 
or reprograming.
The transcription factor LSF (Late SV40 
Factor), also known as TFCP2, is involved in many 
biological events, including cell cycle, DNA synthesis 
and cell survival [29, 30]. In HCC cell lines, LSF also 
regulates genes involved in invasion, angiogenesis, 
and chemoresistance, consistent with its oncogenic 
and metastatic role in HCC [30]. LSF is overexpressed 
in human HCC cell lines when compared to normal 
hepatocytes. Furthermore, in more than 90% of cases 
of patient HCC samples, LSF expression levels show 
significant correlation with the stages and grades of the 
disease [31]. In a subsequent study, Grant et al., identified 
a small molecule factor quinolinone inhibitor 1 (FQI1) that 
effectively inhibits LSF DNA-binding activity [32]. FQI1 
also dramatically displayed anti-proliferative activity in 
LSF overexpressing cells, including HCC cells, leading 
to rapid apoptosis in cell culture and inhibition of HCC 
growth in multiple mouse tumor models [32, 33].
Structural predictions of the LSF protein family 
suggest that they coevolved independently with the critical 
cell cycle regulator p53, as they contain a similar binding 
motif [34]. Based on this observation several functional 
hypotheses on structure-function relationships between 
LSF and p53 have been drawn. Since p53 can directly 
interact and cooperate with DNMT1 to selectively repress 
p53-regulated genes, we attempted to examine if LSF 
binds DNMT1 and accessory factor UHRF1, and if this 
interaction is affected by its inhibitor FQI1, leading to 
epigenome alterations.
RESULTS
LSF-DNMT1 complex in cells
The transcription factors of the LSF family are 
characterized by the possession of a distinctive DNA-
binding domain that bears no clear sequence relationship 
to other known DNA-binding domains [35]. However, 
based on structural predictions, a common origin for the 
LSF and the p53 has been proposed based on similarities 
in the folding of their DNA-binding domains [34]. Since 
p53 recruits DNMT1 and promotes DNA methylation in 
a p53 dependent manner [25], we investigated if such a 
relationship exists between DNMT1 and LSF. We immune-
precipitated human cell (HEK293T) nuclear extract with 
anti-LSF antibody along with an anti-IgG control and 
probed for DNMT1. Indeed, a full-length and a shorter 
form of DNMT1 were detected (Figure 1A). To confirm 
that it was the DNMT1 complex, the same blot was 
probed for UHRF1, an essential partner of DNMT1 during 
DNA methylation (Figure 1A). UHRF1 was observed 
as a co-immunoprecipitated product. This strengthened 
our conclusion that LSF indeed is in a complex with 
DNMT1 machinery in the cell. For visualization of 
this interaction, we also co-expressed FLAG-LSF and 
DsRed-DNMT1 fusions in COS-7 cells. The staining 
pattern of LSF within the cells was largely cytoplasmic, 
but a small but significant percentage of LSF were found 
inside the nucleus, colocalizing with DsRed-DNMT1 as 
was observed by a punctate yellow merged pattern with 
a pearson correlation coefficient of 0.3 (Figure 1B). Both 
DNMT1 and LSF are multi-domain proteins (Figure 1C). 
To determine if the interaction between DNMT1 and 
LSF is direct and which domains are involved in binding, 
we performed GST-pulldown assays. Overlapping GST-
fusions representing the entire length of DNMT1 were 
bound to beads and incubated with a purified MBP-LSF 
fusion. After a thorough wash to remove non-bound LSF, 
the bound proteins were immunoblotted and probed for 
LSF. LSF binds to fragments representing the amino 
terminus regulatory region of DNMT1 (amino acids 
1-446 and 431-836) (Figure 1D). In a reciprocal assay, 
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overlapping GST-fusions representing the entire length of 
LSF bound to the beads were incubated with purified full-
length DNMT1 and after a thorough wash to remove non-
bound DNMT1, the bound proteins were western-blotted 
and probed with anti-DNMT1 antibody. DNMT1 binds 
to fragments representing both the carboxy terminus and 
DNA interaction regions of LSF (amino acids 380-502 and 
65-259) (Figure 1E).
FQI1 dissociates LSF-DNMT1 complex in vitro 
and in cells
We incubated purified DNMT1 with increasing 
amounts of His-LSF recombinant protein to determine 
its influence on DNA methylation (Figure 2A) and thus 
the biological significance of DNMT1-LSF interactions. 
Indeed, as the molar ratio of His-LSF to DNMT1 
increased from 2:1 to 4:1, the methyltransferase activity of 
DNMT1 increased about two-fold (Figure 2A). However 
using similar reaction conditions, the presence of FQI1 
inhibitor negated the methyltransferase stimulation. As 
controls, addition of MBP (maltose binding protein) 
protein alone or in the presence of 5 μM FQI1 had no 
effect on methyltransferase activity (Figure 2A). This 
result along with the GST pull-down assays suggest that 
LSF may activate DNA methylation by direct interaction 
with DNMT1, and by antagonizing this interaction, FQI1 
prevents stimulation of methyltransferase activity.
We hypothesized that if LSF were an epigenetic 
modulator by recruitment of DNMT1, dissociation of 
Figure 1: LSF directly binds DNMT1. A. Immunoprecipitation of endogenous LSF with DNMT1 and UHRF1 in cellular extracts. 
Antibodies used for the western blot are indicated on the right. Two different isoforms of DNMT1 are detected by the anti-DNMT1 
N-terminus antibody. B. Colocalization of DNMT1 and LSF in COS-7 cells. Plasmids expressing FLAG-LSF and DsRed-DNMT1 (red) 
were transfected into the cells; the anti-FLAG antibody reveals LSF (green). The merged image indicates colocalization by the yellow 
punctate pattern of nuclear LSF and DNMT1. C. Schematic structure of human DNMT1 and LSF protein. The numbers indicate amino 
acid residues. NLS: nuclear localization signal; RFD: replication fork binding domain; CXXC: DNA binding domain of DNMT1; BAH1-
BAH2: bromo-adjacent homology domains; (GK)n: GK repeats; DBD: DNA-binding domain; TD: tetramerization domain; and DD: 
dimerization domain. D. GST-pull down analysis of various overlapping domains of DNMT1 with purified full-length LSF, as MBP-LSF 
fusion protein. E. GST-pull down analysis of various overlapping domains of LSF with purified full-length DNMT1. Antibodies used for 
immunoblotting are indicated on the bottom of C and D.
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DNMT1-LSF complex resulting from addition of FQI1 
would lead to expression of DNA hypomethylation-
dependent cellular genes. For validation, we performed 
two different experiments, testing the sensitivity of the 
LSF-DNMT1 interaction to FQI1, both in vivo and in 
vitro. To avoid possible cellular toxicity we incubated 
HEK293T cells with increasing concentrations of FQI1 
and found 2.5 μM as the optimal concentration (data 
not shown). First, we treated HEK293T cells with 2.5 
μM FQI1 to determine if the inhibitor has any effect on 
DNMT1, UHRF1 and LSF gene expression. Indeed, FQI1 
had no effect on UHRF1 and LSF protein levels and small 
reduction of DNMT1 level (Supplementary Figure S1). To 
determine if a small reduction of DNMT1 has any effect 
on DNA methylation we performed nucleotide analysis of 
genomic DNA after 48 hrs of FQI1 treatment. We did not 
observe any difference in the global 5mC (control 3.0% 
vs. FQI1 treated 3.04% of total cytosine) or 5hmC content 
(0.03% of total 5mC) indicating that a slight reduction of 
DNMT1 level does not change 5mC or 5hmC levels.
Therefore, we measured DNMT1 and LSF 
complex formation and secondly, we also performed 
Figure 2: LSF stimulates DNMT1 and FQI1 negates methyltransferase activation. A. Schematic diagram of methyltransferase 
assay in the absence or presence of FQI1 (left panel). DNMT1 assay performed in the presence of the indicated amounts of LSF, plus FQI1 
(2.5 μM) or FQI1 (5 μM) demonstrating the effect of FQI1 on DNA methylation. Note that addition of FQI1 alone in the DNMT1 reaction 
with or without control MBP protein had no effect on DNA methyltransferase activity. B. The cells were treated with DMSO or FQI1 and 
nuclear extract was used for immunoprecipitation of DNMT1 to reveal the degree of LSF binding. Antibodies used for western blots are 
indicated on the right. C. The cells were treated with DMSO or FQI1 and nuclear extract was used for immunoprecipitation of LSF to 
reveal the degree of DNMT1 binding. Antibodies used for western blots are indicated on the right. D. GST-pull down analysis of various 
overlapping domains of LSF and purified full-length DNMT1 in the presence or absence of FQI1. LSF1-502, LSF380-502, LSF65-259 
represents LSF full length, LSF Ubiquitin domain, and LSF DNA binding domain respectively. Ponceau staining of the gel is shown to 
evaluate protein loading. Note that the level of GST-full length LSF is lower than those of the other proteins, which is reflected in the 
decreased amounts of associated DNMT1 with the full-length LSF. The degree of DNMT1 binding is revealed upon immunoblotting with 
anti-DNMT1 antibody.
Oncotarget83631www.impactjournals.com/oncotarget
GST pull-down assays in the presence of 2.5 μM FQI1. 
Immunoprecipitation of endogenous DNMT1 in the 
presence of DMSO control resulted in LSF pull-down 
and addition of FQI1 into the cells resulted in dissociation 
of DNMT1 and LSF, since LSF was greatly diminished 
in the pull-down (Figure 2B). In a reciprocal experiment 
using anti-LSF antibody for immunoprecipitation in the 
presence of DMSO control or FQI1, a similar result was 
observed with severe reduction of DNMT1 in the complex 
(Figure 2C). These results indicate that FQI1 not only 
inhibits the ability of LSF to bind DNA in cells, as shown 
earlier [32], but that it is also a potent destabilizer of LSF-
DNMT1 complex formation. GST-pull down assay in 
the presence of FQI1 also displayed either inhibition of 
complex formation or complex dissociation between LSF 
and DNMT1. Interestingly, FQI1 diminished association 
between both full length LSF and the carboxy-terminal 
domain of LSF with DNMT1, but not that between the 
DNA-binding domain of LSF and DNMT1. Full-length 
LSF binding with full-length DNMT1 was reduced 2 
fold by FQI1, and that of the C-terminal LSF domain 
was reduced 2 fold by FQI1 (Figure 2D). Together, these 
results show that binding of FQI1 to LSF may indeed 
destabilize its binding to DNMT1.
FQI1 promotes aberrant DNA methylation
Since FQI1 inhibits LSF-DNMT1 complex 
formation, we performed reduced representation bisulfite 
sequencing (RRBS) to determine the methylation pattern 
and differences between control, DMSO-treated and FQI1-
treated HEK293T genomes. Libraries were sequenced on 
an Illumina GAII platform. For each biological replicate, 
greater than 15 million of 72 bp high-quality paired-end 
reads (Phred score > 20, adaptor trimmed) were uniquely 
mapped to human genome hg19. With a minimum read 
coverage threshold of three, about 6.8 million average 
CpG sites were covered by each RRBS library, which 
represents about 25% and 23% of the total CpG sites, 
respectively, for DMSO and FQI1 treated human genome 
libraries.
At the single base resolution level, 9775 
differentially methylated CpG sites were identified. The 
number of hypermethylated and hypomethylated DMR 
were 4666 and 5109 respectively, accounting overall 
for a small percentage (~2.3%) of hypomethylation 
across the genome (Figure 3A). We further clustered the 
DMR based on their distribution on genetic elements. 
Indeed, all DMRs were found in known genes, introns 
and CpG island regions including the transcription 
start sites, suggesting FQI1-mediated aberrant DNA 
methylation may have functional consequence in gene 
expression (Figure 3B). We also characterized the DMRs 
by distribution of number of CpG sites per DMR. The 
majority of DMR contained ~4 CpG sites, and almost all 
DMRs had less than 10 CpGs representing both hyper and 
hypomethylated sequences (Figure 3C). Further DMR 
width analysis showed that all DMRs are less than 400 
bps and majority are ~80 bps (Figure 3D). In summary of 
the DMR analysis, hypermethylation was observed in the 
DMRs when the number of CpGs in the DMR is relatively 
lower; as the number of CpGs in the DMR increased, there 
is a trend towards hypomethylation. Also as the size of 
the DMR increases we observed a similar trend from 
hypermethylation to hypomethylation.
FQI1 alters gene expression
LSF functions both as a transcription activator 
and repressor. It binds DNA regions as a homotetramer, 
and regulates a variety of cellular promoters. FQI1 is an 
antagonist to the DNA binding activity of LSF, and also 
promotes aberrant DNA methylation. Therefore both 
inhibiting binding of LSF to DNA and destabilizing its 
complex with DNMT1 would lead to aberrant gene 
expression. Therefore, transcriptional changes are of 
significant interest to understand the mechanisms of FQI1 
cellular activity. We performed RNA-seq in triplicate with 
control and FQI1-treated biological samples. Clustering 
of samples based on Euclidean distance demonstrated 
good correlation within the replicates for control and 
treatment groups. However, there is a clear difference 
between control and treatment groups (Supplementary 
Figure S2). About 42 million of the 72-bp read pairs were 
mapped to hg19 for each library, and about 38 million 
mapped reads in each library could be assigned to a 
known gene. A total number of 4337 genes were found 
to be differentially expressed, where 2502 genes were up-
regulated and 1835 genes were down-regulated in cells 
treated with FQI1 (Figure 4A). The regularized logarithm 
(rlog) transformed read counts of the top 100 genes with 
lowest adjusted p value were plotted on the heatmap, 
demonstrating clustering of control and FQI1-treated 
triplicates displaying differential expression (Figure 4B). 
Pathway analysis performed using GAGE [36] with high 
stringency (q value <0.01) revealed enrichment of genes 
involved in proteasome, spliceosome, RNA transport, 
protein processing in ER, and MAP kinase signaling 
pathways (Supplementary Table S1). FQI1 predominantly 
inhibited the DNA replication pathway (Supplementary 
Figure S1). Specific genes upregulated by FQI1 treatment 
included Aurora Kinase A (AURKA), suppressor APC 
Domain Containing 2 (SAPCD2), Kinesin Heavy Chain 
Member 2A (KIF2A), all of which were validated by RT-
qPCR. All upregulated genes were activated within the 
first 12 h of FQI1 treatment (Figure 4C). Similarly among 
down regulated genes, MCM5, MCM6 and MCM7 were 
validated and repressed (Figure 4C). Therefore FQI1’s 
cellular influence involves both up and down regulation 
of gene expression and/or mRNA stability.
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Correlations between differentially methylated 
regions and gene expression
Further characterization of FQI1-mediated 
aberrant DNA methylation led us to identify many 
genic regions with either hyper or hypomethylations. 
RRBS genic regions were chosen for demonstration 
of DMRs. For example, chr19: 2,128,860 – 2,129,304, 
chr19: 54,677,584 – 54,678,078, and chr19: 14,590,249 
– 14,590,472 were hypomethylated and chr4: 4,765,010 
– 4,765,535, chr17: 73,545,489 – 73,546,127, and 
chr18: 13,677,234 – 13,677,609 were hypermethylated 
(Figure 5A). Since FQI1 promotes aberrant DNA 
methylation, we correlated DMR with the transcriptomic 
data. A driving force for this analysis was that 1678 
DMRs located in TSS +- 2kb regions were associated 
with genes that were differentially regulated in the 
presence of FQI1. Therefore, the DMRs located 
near transcription initiation sites were clustered into 
hypomethylated or hypermethylated regions and 
then correlated with RNA-seq (log2 fold changes) 
data for the nearby gene. Hypermethylated DMRs 
were associated with no changes in gene expression 
(29.6%), reduced gene expression (9.1%) and elevated 
gene expression (9.5%). Similarly, hypomethylated 
DMRs represented no changes in gene expression 
(32.2%), reduced gene expression (9.5%) and elevated 
gene expression (10.2%) suggesting aberrant DNA 
methylation by FQI1 has a profound effect on aberrant 
gene expression (Figure 5B).
Since DNA methylation is historically known as 
a gene repressor signal, we analyzed the previously 
Figure 3: FQI1 treatment triggers alteration of genome wide DNA methylation. A. Volcano plot showing differentially 
methylated regions in the genome after HEK293T cells were treated with 2.5 μM FQI1 for 48 hrs. Green dots represent hypomethylated 
DMRs and red dots represent hypermethylated DMRs. Total number of hyper and hypomethylated DMRs are annotated in the plot. B. Bar 
graph showing the distribution of the 9775 DMRs in various regions of the genome. Each DMR is included in all appropriate categories. 
C. Density plot displaying the distribution of number of CpGs in DMRs. Red graph represents hypermethylated DMRs, green represents 
hypomethylated DMRs and blue represents all DMRs together. D. Density plot displaying the distribution of the size of DMRs. Red graph 
represents hypermethylated DMRs, green represents hypomethylated DMRs and blue represents all DMRs together.
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demonstrated distribution in unperturbed HEK293T 
cells for H3K4me3, H3K27ac, and H3K36me3 
(activation signature) and H3K4me1 and H3K9me3 
(repression signature) histone marks within 6 kb 
around the 1678 DMRs near the transcription start sites 
(Supplementary Figure S3 and S4). Both hyper- and 
hypomethylated DMRs that exhibited transcriptional 
activation upon addition of FQI1 were already enriched 
for H3K4me3 and H3K27ac (Supplementary Figure S3 
and S4). Notably, in hypomethylated DMRs the ground 
state H3K4me3 signature was more pronounced in gene 
sets in which expression was increased upon FQI1 
treatment, compared to those with either a decrease 
or no change in gene expression coinciding with loss 
of nucleosome (Supplementary Figure S4). We further 
characterized these DMRs near transcription start sites 
using WebGestalt, a web-based gene set analysis tool kit 
to perform GO analysis. Both hyper and hypomethylated 
DMRs with no change in transcript levels displayed 
strong enrichment for metabolic pathways (e.g. FBP1, 
DNMT3A, NMNAT1, AK7, FBP2, B3GAT3, ADA). In 
the case of genes with decreased expression, we observed 
Figure 4: Transcriptome analysis of FQI1- versus vehicle-treated HEK293T cells. A. MA plot analysis of FQI1 vs DMSO 
control samples displaying distribution of up-regulated (blue), down-regulated (red) and unchanged (grey) gene expression. B. Heatmap 
showing the distribution of top 100 genes (descending order) for three replicates of DMSO and FQI1 treated samples. C. qPCR validation 
of genes identified with significantly altered expression from RNAseq. Top panel shows genes with increased expression and bottom panel 
shows genes with decreased expression.
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enrichment of G1 to S cell cycle control (e.g. POL2A, 
MCM2) and DNA replication (e.g. PRIM1) pathways 
for hypermethylated DMRs. For hypomethylated DMRs 
with decreased expression, GO terms for metabolic 
pathways (e.g. GSTZ1, ALDH5A1, NDUFS1) were 
enriched. Finally, for DMRs whose associated genes 
had increased expression upon treatment with FQI1, 
we observed enrichment of GO terms for pathways in 
cancer (e.g. PIAS4, SMAD3, TRAF4, MAP2K1) and 
RNA transport (e.g. NUP188, EIF3A, NUP35, RAN) in 
both hyper and hypomethylated DMRs (Supplementary 
Table S2). Thus, FQI1 treatment impacts the cell cycle 
and a number of growth signaling pathways, with 
potential to impact cancer development.
Transcription factor binding may be altered by 
FQI1-mediated DMRs
We performed in silico analysis for transcription 
factor-binding motifs in both hypermethylated and 
hypomethylated DMRs to better understand the effect of 
aberrant DNA methylation at DMRs on gene expression. 
DMRs with hypomethylation did not reveal any 
significant enrichment for transcription factor binding 
motifs. However, we found enrichment of motifs for 
STAT (Stat3), ETS (Elk4, Elk1, Fli1), Zinc Finger 
(Maz, Znf263, REST-NRSF), and bZIP (c-Jun-CRE, 
Atf1) family of transcription factors in hypermethylated 
DMRs (Supplementary Table S3). Several studies have 
Figure 5: Correlation of differential DNA methylation and altered gene expression with FQI1 treatment. A. Tracks 
showing hyper and hypomethylated DMRs. Blue lines represent CpG methylation levels in DMSO control triplicates and red lines represent 
CpG methylation levels in FQI1 treated triplicates. Pink shaded region depicts the DMR and the ticks on the X-axis represent the location 
of CpGs. B. Heatmap showing the correlation between hyper and hypomethylated DMRs and their corresponding expression levels. 
Clustering is performed along the rows for 1678 DMRs located near the TSS of the genes represented by the RNAseq data.
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demonstrated the negative correlation of CpG methylation 
within binding sequence with transcription factor binding, 
particularly for STAT3, c-Jun-CRE and ATF1 [37–40].
DISCUSSION
The transcription factor LSF is a promising protein 
target for chemotherapy in hepatocellular carcinoma. 
It is highly expressed in HCC patient samples and cell 
lines, and promotes oncogenesis in a rodent xenograft 
HCC model [31, 32]. FQI1 promotes apoptosis in LSF-
overexpressing cells, including HCC cells, although 
primary or immortalized hepatocytes remain unaffected, 
demonstrating its cancer selectivity [32]. Limited data on 
in vitro treatment of human HCC cells with LSF inhibitors 
demonstrated mitotic arrest [33]. However, the molecular 
mechanism of this inhibitor in cells is significantly 
lacking. Factor quinolinone inhibitor 1 (FQI1) is a small 
molecule that effectively and selectively inhibits LSF 
cellular activity by inhibiting LSF DNA-binding activity 
both in vitro and in cells [32].
Here we have used human HEK293T cells as a 
model system to study the effect of FQI1 on its epigenome 
and gene transcription. HEK293T cells produce similar 
quantities of LSF as that in HCC cell lines and offer a 
more homogenous genome compared to cancer cells. Our 
study suggested that exposure of cells to FQI1 alter the 
epigenome. Indeed, DNA methylation, a major component 
of the epigenome showed aberrant DNA methylation and 
gene expression covering over 2K DMRs. As shown, 
FQI1 can cause both hyper- and hypomethylation 
resulting in either activation or repression of gene 
expression. One hypothesis centered on involvement of 
differential methylation posits that LSF recruits DNMT1 
to gene regulatory regions to repress LSF target genes by 
traditional methylation mediated gene repression. Then, 
FQI1 would disrupt the LSF-DNMT1 interaction (in 
addition to removing LSF from the DNA), which would 
lead to poor DNMT1 targeting resulting in aberrant DNA 
methylation and altered DMR (Figure 6A). In addition, 
LSF target genes that are generally transcriptionally 
activated or repressed by LSF binding (associated with 
Figure 6: Working models of LSF-DNMT1 complex dissociation by FQI1 and aberrant DNA methylation. A. LSF is depicted 
as dimer in solution and DNMT1 as monomer. LSF and DNMT1 form a complex for sequence specific gene methylation and gene repression. 
FQI1 directly binds LSF and interferes with the DNMT1-LSF complex formation leading to mistargeting of DNMT1 resulting in aberrant DNA 
methylation and both transcriptional activation (green) and repression (red). B. FQI1 binds to LSF and inhibits its binding on DNA. LSF that is 
targeted for binding to DNA will dissociate FQI1 before binding as tetramer for gene regulation (both positive and negative).
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cofactors other than DNMT1) will lose LSF-mediated 
gene regulation in the presence of FQI1 (Figure 6B). 
Finally, some of the genes whose expression was 
significantly altered downstream of FQI1 treatment (by 
either mechanism in Figure 6A or 6B) are transcription 
factors whose binding motifs were overrepresented in 
DMRs (e.g. STAT3, ELK4, ATF2 and REST), suggesting 
that the differential gene expression could include a 
downstream, secondary wave of regulation.
Other transcription factors have been associated 
with aberrant gene expression patterns in cancer, and 
also serve as the convergence points of oncogenic 
signaling that are functionally altered in many cancers. 
Our data suggest that LSF may behave similarly. 
For example, the Myc oncogene, a member of the 
bHLHZip family of transcription factors, is well known 
for its contribution to cancer by protein/protein and 
protein/DNA interactions. Myc forms heterodimers 
with Max, and binds in the promoters of pro-growth 
and proliferation targets and thereby activates their 
expression. Activation of these Pol II targets is mediated 
by the recruitment of different chromatin modifying 
activities. Myc binds the corepressor Dnmt3a and 
associates with DNA methyltransferase activity in vivo. 
Indeed, Myc and Dnmt3a form a ternary complex with 
Miz-1, which then represses the p21Cip1 promoter 
[41]. Since LSF association with DNMT1 resulted 
in activation of DNA methylation, we speculate that 
interaction between both may trigger hypermethylation 
of CpG islands containing tumor suppressor genes. It is 
plausible that the interaction of LSF with the N-terminal 
of DNMT1 may facilitate release of the catalytic domain 
from an auto-inhibitory fold formed by interactions 
between the DNMT1 N- and C-terminal regions thus 
aiding DNA hypermethylation.
Small molecule inhibitors that can alter the 
epigenome have become increasingly important in cancer 
therapy [42]. Recently, small molecule inhibitors such 
as Decitabine have been used to treat myelodysplastic 
syndrome (MDS) [43]. This potent DNA methyltransferase 
inhibitor alters the epigenome in a rapid manner, leading 
to apoptosis. From the current study, we also observed 
FQI1 triggers signaling pathways involved in cell cycle 
regulation.
Recent studies underscore the extensive 
reprogramming of every component of the epigenetic 
machinery in cancer including DNA methylation, 
histone modifications, nucleosome positioning and non-
coding RNAs. Epigenome reprogramming has a diverse 
effect on genome integrity and transcriptional output. 
A comprehensive understanding of the numerous and 
diverse molecular phenomena occurring in the epigenome 
of normal and malignant cells, and the pathways altered 
by small molecule drugs, will hopefully provide novel 
mechanistic insights into more effective epigenetic cancer 
treatment strategies.
MATERIALS AND METHODS
Cell culture, immunoprecipitation and 
immunofluorescence
HEK293T and COS7 cells were cultured in DMEM 
media supplemented with 10% fetal bovine serum. For 
FQI1 treatment, HEK293Tcells were treated with 2.5 μM 
of FQI1 for 24 h at 37 ˚C.
Immunoprecipitation and immunofluorescence were 
carried out as described previously [44, 45]. For the co-
IP of DNMT1 and LSF in HEK293T cells, 1 mg of the 
whole cell lysate was incubated with 2 μg of anti-DNMT1 
antibody (sc-20701, Santa Cruz) or anti-LSF antibody 
(Millipore). IP reactions were blotted with anti-DNMT1 
(M0231S, New England Biolabs), anti-LSF (610818, 
BD) and anti-UHRF1 (612264, BD) antibodies as per the 
manufacturer’s dilution recommendations. Normal IgG 
was used as a control in all IP reactions. For the detection 
of DNMT1 and LSF colocalization, COS7 cells were 
grown on coverslips and co-transfected with DsRed-
DNMT1 and 3xFLAG-LSF plasmids. DsRed-DNMT1 
was visualized with an excitation wavelength of 594 nm, 
epitope tagged LSF was detected by mouse anti-FLAG 
antibody (F3165, Sigma-Aldrich) and visualized with 
an anti-mouse IgG coupled with Alexa Fluor 488 dye 
(Molecular Probes). DAPI was used for nuclear staining. 
Pearson’s correlation coefficient was calculated using NIH 
imageJ/JACoP [46].
GST-pull down assays
For GST pull-down assays, GST – LSF fragments 
(1-180, 169-319, 306-420, 383-503, 65-259 (DNA 
Binding Domain), 326-385 (Sterile Alpha Motif, or SAM, 
domain, [47]) amino acids) were cloned into the pGEX-
5X-1 vector (GE Healthcare), overexpressed in E. coli, 
and GST-tagged expressed proteins were captured using 
Glutathione Sepharose beads (GE Healthcare). Sepharose 
beads containing 10 μg of fusion protein were incubated 
with 200 ng of recombinant baculovirus expressed 
DNMT1. Protein bound to the beads was resolved by 
SDS-PAGE. DNMT1 was visualized by immunoblotting 
by using Anti-DNMT1 (M0231S, New England Biolabs). 
For the reciprocal experiment, GST-DNMT1 fusion beads 
were incubated with 1 μg of purified MBP-LSF protein. 
LSF was visualized by immunoblotting by using Anti-LSF 
(610818, BD).
DNA methyltransferase assays
DNA methyltransferase assays were carried out 
as described previously [48]. The role of LSF and FQI1 
on DNA methylation was determined by assaying the 
activity of DNMT1 in the presence and absence of LSF 
and FQI1. Methylation reactions were performed using 
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80 nM DNMT1, 100 ng hemimethylated substrate and 5 
μM tritiated AdoMet, incubating for 30 minutes at 37˚C 
along with various concentrations of LSF. Samples were 
processed using a filter disc method and the [3H]CH3 
incorporated into the DNA was determined using a liquid 
scintillation counter.
Genome-wide DNA methylation analysis
Genome-wide DNA methylation analysis was 
carried out using the Reduced Representation Bisulfite 
Sequencing method [49]. Genomic DNA (2 μg) isolated 
from HEK293T treated with FQI1 or DMSO control 
(biological triplicates) for 48 hrs was digested with MspI, 
end-repaired and dA-tailed. Methylated NEB Illumina 
loop adaptor was ligated to the processed fragmented DNA 
(E7370S, New England Biolabs) and digesting the uracil 
with USER enzyme opened the adaptor loop. Ligation 
products were size-selected for 150 to 400 bp fragments 
on 2% agarose gels and bisulfite converted using the EZ 
DNA Methylation Kit (Zymo Research). Libraries were 
enriched by PCR using EpiMark Hot Start Taq DNA 
Polymerase (New England Biolabs) and sequenced on 
the Illumina GAII platform with 72 bp paired-end reads. 
Libraries were made and sequenced using two independent 
replicates.
Adaptor and low quality sequences (Phred score < 
20) were trimmed from sequencing reads using the trim_
galore package (http://www.bioinformatics.babraham.
ac.uk/projects/trim_galore/) with the parameter of –RRBS 
–paired. Reads were mapped to hg19 using Bismark with 
Bowtie2 [50]. CpG methylation levels were calculated 
with uniquely mapped reads using Bismark methylation 
extractor with the parameter of -p –no_overlap and 
a minimum coverage of 3. Differential methylation 
analysis was carried out using the bsseq R package [51]; 
CpGs present in at least two replicates of each group 
were retained for downstream analysis. DMRs were 
identified containing a minimum of 3 CpGs and mean 
difference between the control and FQI1-treated samples 
of greater than 0.1 using BSmooth package [51]. DMRs 
were annotated by mapping the genomic coordinates to 
various genomic regions, i.e., ±2 kb of transcription start 
site (TSS), CpG islands in promoter, CpG islands in gene 
body, CpG islands in deserts, CpG islands, CpG island 
± 2kb, 5’ UTR, coding exon, intron, 3’ UTR, and known 
genes using BEDTools [52]. DMRs were visualized by 
plotting the CpG methylation levels in a 5 kb window 
around the DMR using bsseq R package. Density plots for 
number of CpGs in DMR and the lengths of DMRs were 
plotted using ggplot2 R package [53].
RNA-seq analysis
Total RNA was extracted using Trizol reagent 
(Invitrogen) from HEK293T cells treated with either 2.5 
μM of FQI1 or 0.01% DMSO for 12 hr at 37°C. RNA-
seq libraries were constructed using the NEBNext® 
Ultra™ Directional RNA Library Prep Kit (New England 
Biolabs). Average insert size of libraries was 200 bp. 
Libraries were sequenced in 76 bp paired-end read mode 
on the IlluminaNextSeq 500 platform. Sequencing reads 
were mapped to hg19 using TopHat2 (-r 60 –library-
type fr-firststrand) [54]. The number of reads mapped 
to each known gene was counted using htseq-count 
tools (-t exon -s reverse –i gene_id) and differential 
gene expression analyzed with DESeq2 [55, 56]. The 
p-value of differential expression was corrected using 
the Benjamini-Hochberg adjustment method. Genes with 
adjusted p-value < 0.01 were considered significantly 
differentially expressed. Sample distance was calculated 
using Euclidean distance on the rlog-transformed counts. 
Heatmaps were generated using the Z-scored-transformed 
rlog values of significantly changed genes (top 100). MA 
plot showing differential expression (log2 fold change) 
versus mean expression value between FQI and control 
was plotted. GO analysis was performed using GAGE 
package (Generally Applicable Geneset Enrichment for 
Pathway Analysis) [57].
Correlation of DNA methylation and gene 
expression change
In order to investigate the correlation of DNA 
methylation alteration and gene expression change after 
FQI1 treatment, we analyzed the differential methylation 
again and this time we focused on the ±2 kb regions 
flanking TSS. Only regions with more than three CpGs 
were kept. Only genes with significant expression changes 
(adj p-value < 0.05) and significant methylation changes 
(q-value < 0.05) were included in the correlation study. 
Genes were clustered based on the CpG methylation 
difference of their TSS ±2 kb regions and their expression 
level using k-means clustering.
Transcription factor binding motif analysis
Presence of transcription factor binding motifs in 
the DMRs (hyper and hypomethylated) associated with 
RNAseq data was evaluated using findMotifsGenome 
function of homer with masked genomic regions [58]. 
Motifs with a p-value of at least 0.01 were considered for 
analysis.
Quantitative PCR analysis of gene expression
HEK293Tcells were treated with 2.5 μM of FQI1 
for 12 or 24 hr at 37°C. Total RNA was extracted using 
Trizol reagent (Invitrogen) from HEK293T treated FQI1, 
or DMSO as a control. 1 μg of total RNA was reverse 
transcribed to cDNA using ProtoScript II First Strand 
cDNA Synthesis Kit (New England Biolabs) and 40 ng 
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cDNA was subjected to real-time PCR analysis using 
SYBR Green Supermix (Bio-Rad). The following primers 
were used: AURKA_F: GCAGATTTTGGGTGGTCAGT, 
AURKA_R: TCTTGAAATGAGGTCCCTGG; SAPC 
D2_F: GAGCAGAACCGACTCCTCAC, SAPCD2_R: 
GGCCCACAAGGACTAGATGA; KIF2A_F: CACCCA 
CCTCAACCAGAACT, KIF2A_R: AGCCAGCCAGAT 
CACAGAGT; MCM5_F: GACTTCATGCCCACCA 
TCTT, MCM5_R: TCACGTGCAGAGTGATGACA; 
MCM6_F: AACCAGCAACTTTCCACCAC, MCM6_R: 
GAAAAGTTCCGCTCACAAGC; MCM7_F: TGAGTTC 
GACAAGATGGCTG, MCM7_R: CCGTAGGTCAT 
TGTCTCGGT; expression change was calculated using 
the 2-ΔΔCt method.
GO analysis
GO analysis for the hypermethylated and 
hypomethylated DMRs was performed using WEB-
based GEne SeT AnaLysis Toolkit (WebGestalt) [57]. 
Annotation of the DMRs was performed using homer and 
the gene names were used as the input for GO analysis 
with default parameters (minimum of 2 hits per category, 
hypergeometric statistics method and “BH” multiple test 
adjustment settings) [58]. Top 10 enriched GO terms from 
KEGG and WIKI pathway analysis were generated.
ChIP fragment depth analysis for histone marks
ChIP-seq data sets for H3K4me3, H3K4me1, 
H3K9me3, H3K27ac and H3K36me3 histone marks in 
HEK293T cell line were downloaded from ENCODE 
(ENCFF001FJF, ENCFF002AAV, ENCFF002AAX, 
ENCFF002ABA, and ENCFF002ABD). Tag densities 
for each data set was calculated using makeTagDirectory 
function of homer package. Further, a histogram of the 
tag densities for each histone mark was plotted using 
the annotate Peaks function of homer by extending ±3 
kb around the DMRs that showed no expression change, 
decreased expression and increased expression in case of 
both hypermethylated and hypomethylated condition [58].
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